Patents by Inventor Donald A. Foster

Donald A. Foster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Complement component C5 iRNA compositions and methods of use thereof
    Patent number: 11873491
    Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: January 16, 2024
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, James Butler, Brian Bettencourt, Anna Borodovsky, Satyanarayana Kuchimanchi, Klaus Charisse, Muthiah Manoharan, Martin A. Maier, Kallanthottathil G. Rajeev, Donald Foster
  • Angiotensinogen (AGT) iRNA compositions and methods of use thereof
    Patent number: 11834661
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the AGT gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an AGT gene and to methods of preventing and treating an AGT-associated disorder, e.g., high blood pressure.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: December 5, 2023
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Donald Foster, Gregory Hinkle, Mark K. Schlegel
  • SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230365965
    Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.
    Type: Application
    Filed: January 17, 2023
    Publication date: November 16, 2023
    Applicant: Genzyme Corporation
    Inventors: Akin Akinc, Alfica Sehgal, Ivanka Toudjarska, Donald Foster, Stuart Milstein, Brian Bettencourt, Martin A. Maier, Klaus Charisse, Satyanarayana Kuchimanchi, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION
    Publication number: 20230287424
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents for administration by inhalation preferably targeting genes expressed in the respiratory system, as well as methods of inhibiting expression of a target gene after administration by inhalation, preferably a gene expressed in the respiratory system.
    Type: Application
    Filed: December 8, 2022
    Publication date: September 14, 2023
    Inventors: Christopher Brown, Donald Foster, Arlin Rogers, Vasant R. Jadhav, Akin Akinc, Amy R. Simon
  • Serpina1 iRNA compositions and methods of use thereof
    Patent number: 11725207
    Abstract: The invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: August 15, 2023
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Mark K. Schlegel, Maja Janas, Vasant R. Jadhav, Donald Foster, Muthiah Manoharan, Kallanthottathil G. Rajeev, Alexander V. Kel'in, Klaus Charisse, Jayaprakash K. Nair, Martin A. Maier, Shigeo Matsuda, Muthusamy Jayaraman, Alfica Sehgal, Christopher Brown, Kevin Fitzgerald, Stuart Milstein
  • TMPRSS6 iRNA compositions and methods of use thereof
    Patent number: 11725209
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: August 15, 2023
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: James Butler, Martin A. Maier, Kevin Fitzgerald, Shannon Fishman, Donald Foster, Vasant R. Jadhav, Stuart Milstein
  • ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230123192
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.
    Type: Application
    Filed: July 1, 2022
    Publication date: April 20, 2023
    Inventors: Donald Foster, Brian Bettencourt, Klaus Charisse, Gregory Hinkle, Satyanarayana Kuchimanchi, Martin A. Maier, Stuart Milstein
  • METHODS AND COMPOSITIONS FOR TREATING AN ANGIOTENSINOGEN- (AGT-) ASSOCIATED DISORDER
    Publication number: 20230002765
    Abstract: The present invention relates to methods of inhibiting the expression of an AGT gene in a subject, as well as methods for treating subjects having an AGT-associated disorder, e.g., hypertension, using RNAi agents, e.g., double stranded RNAi agents, targeting the AGT gene. The invention also relates to methods of decreasing blood pressure levels in a subject using such RNAi agents to inhibit expression of an AGT gene.
    Type: Application
    Filed: May 13, 2022
    Publication date: January 5, 2023
    Inventors: Donald Foster, Sagar Agarwal, Stephen Albert Huang, Jae Kim
  • COMPOSITIONS AND METHODS FOR SILENCING UGT1A1 GENE EXPRESSION
    Publication number: 20220389429
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the UGT1a1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of UGT1a1.
    Type: Application
    Filed: October 2, 2020
    Publication date: December 8, 2022
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: DONALD FOSTER, JAMES MCININCH
  • Modified RNA agents with reduced off-target effect
    Patent number: 11504391
    Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. The antisense strand of the dsRNA molecule comprises at least one thermally destabilizing nucleotide occurring at a seed region; the dsRNA comprises at least four 2?-fluoro modifications, and the sense strand of the dsRNA molecule comprises ligand, wherein the ligand is an ASGPR ligand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: November 22, 2022
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Mark K. Schlegel, Maja Janas, Vasant R. Jadhav, Donald Foster, Muthiah Manoharan, Kallanthottathil G. Rajeev, Muthusamy Jayaraman, Alexander V. Kel'in, Shigeo Matsuda, Klaus Charisse, Jayaprakash K. Nair, Martin A. Maier, Alfica Sehgal, Christopher Brown, Christopher Theile, Stuart Milstein
  • Angiotensinogen (AGT) iRNA compositions and methods of use thereof
    Patent number: 11419942
    Abstract: The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the angiotensinogen (AGT) gene, and methods of using such RNAi agents to inhibit expression of AGT and methods of treating subjects having an AGT-associated disorder, e.g., hypertension.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: August 23, 2022
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Donald Foster, Brian Bettencourt, Klaus Charisse, Gregory Hinkle, Satyanarayana Kuchimanchi, Martin A. Maier, Stuart Milstein
  • COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20220090068
    Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.
    Type: Application
    Filed: July 12, 2021
    Publication date: March 24, 2022
    Inventors: Kevin Fitzgerald, James Butler, Brian Bettencourt, Anna Borodovsky, Satyanarayana Kuchimanchi, Klaus Charisse, Muthiah Manoharan, Martin A. Maier, Kallanthottathil G. Rajeev, Donald Foster
  • Silverwear Protective Supports
    Publication number: 20220071428
    Abstract: A protective support for an article of silverwear has a body with a lowermost interface to a tabletop and an uppermost region presenting a cradle opening vertically upward for restraining a silverwear utensil, the cradle having a bottom restraint supporting the silverwear utensil, and side restraints constraining the supported silverwear utensil from moving off the support on either side.
    Type: Application
    Filed: September 10, 2020
    Publication date: March 10, 2022
    Inventors: Bart Berardo, Donald Foster
  • MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDE
    Publication number: 20210388356
    Abstract: One aspect of the present invention relates to double-stranded RNA (dsRNA) agent capable of inhibiting the expression of a target gene. Other aspects of the invention relate to pharmaceutical compositions comprising these dsRNA molecules suitable for therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA molecules, e.g., for the treatment of various disease conditions.
    Type: Application
    Filed: November 5, 2019
    Publication date: December 16, 2021
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Donald FOSTER, Mark K. SCHLEGEL, Christopher BROWN
  • Complement component C5 iRNA compositions and methods of use thereof
    Patent number: 11162098
    Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: November 2, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Kevin Fitzgerald, James Butler, Brian Bettencourt, Anna Borodovsky, Satyanarayana Kuchimanchi, Klaus Charisse, Muthiah Manoharan, Martin A. Maier, Kallanthottathil G. Rajeev, Donald Foster
  • ANGIOTENSINOGEN (AGT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210310006
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the AGT gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an AGT gene and to methods of preventing and treating an AGT-associated disorder, e.g., high blood pressure.
    Type: Application
    Filed: April 7, 2021
    Publication date: October 7, 2021
    Inventors: Donald Foster, Gregory Hinkle, Mark K. Schlegel
  • SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210269796
    Abstract: The invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Serpina1 gene, and methods of using such RNAi agents to inhibit expression of Serpina1 and methods of treating subjects having a Serpina1 associated disease, such as a liver disorder.
    Type: Application
    Filed: March 8, 2021
    Publication date: September 2, 2021
    Inventors: Mark K. Schlegel, Maja Janas, Vasant R. Jadhav, Donald Foster, Muthiah Manoharan, Kallanthottathil G. Rajeev, Alexander V. Kel'in, Klaus Charisse, Jayaprakash K. Nair, Martin A. Maier, Shigeo Matsuda, Muthusamy Jayaraman, Alfica Sehgal, Christopher Brown, Kevin Fitzgerald, Stuart Milstein
  • SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210254063
    Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.
    Type: Application
    Filed: December 21, 2020
    Publication date: August 19, 2021
    Applicant: Genzyme Corporation
    Inventors: Akin Akinc, Alfica Sehgal, Ivanka Toudjarska, Donald Foster, Stuart Milstein, Brian Bettencourt, Martin A. Maier, Klaus Charisse, Satyanarayana Kuchimanchi, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20210163952
    Abstract: The invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the TMPRSS6 gene, and methods of using such RNAi agents to inhibit expression of TMPRSS6 and methods of treating subjects having a TMPRSS6 associated disorder, e.g., an iron overload associated disorder, such as ?-thalassemia or hemochromatosis.
    Type: Application
    Filed: October 5, 2020
    Publication date: June 3, 2021
    Inventors: James Butler, Martin A. Maier, Kevin Fitzgerald, Shannon Fishman, Donald Foster, Vasant R. Jadhav, Stuart Milstein
  • Angiotensinogen (AGT) iRNA compositions and methods of use thereof
    Patent number: 11015201
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the AGT gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an AGT gene and to methods of preventing and treating an AGT-associated disorder, e.g., high blood pressure.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: May 25, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Donald Foster, Gregory Hinkle, Mark K. Schlegel